Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting
2007

Impact of GP IIIa Gene Polymorphism on Heart Stenting Outcomes

Sample size: 963 publication Evidence: moderate

Author Information

Author(s): Claire Le Hello, Rémy Morello, Agnès Lequerrec, Christine Duarte, John Riddell, Martial Hamon

Primary Institution: Caen Universitary Hospital

Hypothesis

Does the GP IIIa PlA1/A2 polymorphism affect long-term outcomes in patients with coronary artery disease after stenting?

Conclusion

The GP IIIa PlA1/A2 polymorphism does not influence the long-term clinical outcome in patients with symptomatic coronary disease undergoing percutaneous coronary intervention with stent implantation.

Supporting Evidence

  • The study involved 1,111 patients, but only 963 were included in the final analysis.
  • The incidence of major adverse cardiac events was similar across different genotype groups.
  • Independent risk factors for adverse outcomes included low left ventricular ejection fraction and lack of certain medications.

Takeaway

This study looked at whether a specific gene change affects heart health after stenting. It found that this gene change doesn't really make a difference.

Methodology

A prospective observational study involving genotyping of 1,111 Caucasian patients treated with coronary stenting, with follow-up for major adverse cardiac events.

Potential Biases

Potential bias due to the study being conducted in a single center and the small sample size of certain genotypes.

Limitations

The study was conducted in a single hospital, had a small number of A2/A2 patients, and a significant number of patients were lost to follow-up.

Participant Demographics

The study included 963 Caucasian patients, with 80.9% males and a mean age of 64.4 years.

Digital Object Identifier (DOI)

10.1186/1477-9560-5-19

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication